Recaticimab, CAS 2361290-85-7

Product Description: Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia[1][2].

Applications: Metabolism-sugar/lipid metabolism

Formula: N/A

References: [1]Xu M, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022 Jan 18;20(1):13. /[2]Jiao J, et al. Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist. World Intellectual Property Organization. WO2022268214.

CAS Number: 2361290-85-7

Molecular Weight: N/A

Compound Purity: 99.71

Research Area: Metabolic Disease

Solubility: 10 mM in DMSO

Target: PCSK9

• Artikelnummer: MEXHY-P99822-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99822-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK